Menu Search
Equities

Sagimet Biosciences Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0O2:FRA

Sagimet Biosciences Inc

Actions
  • Price (EUR)4.60
  • Today's Change0.02 / 0.44%
  • Shares traded3.00
  • 1 Year change+3.60%
  • Beta--
Data delayed at least 15 minutes, as of Feb 09 2026 08:55 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis. The Company is also exploring the use of its FASN inhibitors, which include denifanstat and its pipeline product candidate, TVB-3567, in acne and in select forms of cancer. Denifanstat is being tested in China by its license partner, Ascletis BioScience Co. Ltd., for moderate to severe acne vulgaris and recurrent glioblastoma multiforme in combination with bevacizumab.

  • Revenue in USD (TTM)0.00
  • Net income in USD-57.67m
  • Incorporated2006
  • Employees14.00
  • Location
    Sagimet Biosciences Inc155 BOVET RD., SUITE 303SAN MATEO 94402United StatesUSA
  • Phone+1 (650) 561-8600
  • Fax+1 (302) 730-1370
  • Websitehttps://sagimet.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.